"2011 was a significant year for Spectral," said Dr. Paul
Walker, President and CEO of Spectral Diagnostics. "The
Company received approval from the U.S. Food and Drug
Administration to expand its Phase III EUPHRATES trial in
severe sepsis and septic shock, completed a $10 million
financing and expanded its investor base. Collectively, these
developments should help the Company achieve its clinical
milestones over the next few years."
Management anticipates there are several factors that could
impact Spectral's valuation in 2012 and beyond. These
include:
- As at December 31, 2011, Spectral has approximately $18.5
million cash and cash equivalents
- The Company's shareholder base has increased to an
estimated 7,000 retail and institutional shareholders
- In 2011, liquidity saw a fourfold increase in daily average
trading volume versus 2010
- The FDA approved the expansion of the trial to 30 clinical
trial sites (from 15), including international locations
- Spectral obtained additional market rights for Toraymyxin
in Canada and announced the planned expansion of the trial
into Canada
- Spectral reorganized for the expansion, including
contracting with a new contract research organization
- Interim clinical data is targeted for the end of 2012, or
early 2013, depending on the site uptake and patient
enrolment rates, with receipt of final data approximately one
year later
- Eli Lilly withdrew Xigris, the only approved drug for severe sepsis, after failing to demonstrate efficacy in a post marketing study
Competitors' trials continue to face recruitment and efficacy challenges that Spectral has planned for
- In addition to Xigris, Eisai's Eritorin failed to
demonstrate efficacy in its Phase III trial for severe
sepsis
- A common challenge for these, and other failed or ongoing
trials, has been the balancing of a desire for rapid patient
recruitment against the need to get the right patients, who
are sick
enough, into the trial in order to demonstrate efficacy
"There are no shortcuts when it comes to running a successful
sepsis clinical trial," added Dr. Walker. "Our focus
continues to be on carefully selecting high performing
clinical sites and enrolling only those endotoxemic patients
at highest risk of sepsis-related mortality. The EUPHRATES
trial is the only late- stage sepsis trial to use a
biomarker, the EAA™ measurement for endotoxin, as entry
criteria to identify patients most likely to respond to
treatment. In this way, we believe that our EUPHRATES trial
is best positioned to have the greatest likelihood of
success."
Spectral is a Phase III company seeking U.S. FDA approval for
its lead theranostics product for the treatment for severe
sepsis and septic shock. Toraymyxin is a therapeutic
hemoperfusion device that removes endotoxin, which can cause
sepsis, from the bloodstream. Directed by the
Company's
Endotoxin Activity Assay (EAA™), the only FDA cleared
diagnostic for the risk of developing sepsis,
Spectral's EUPHRATES trial is the world's first
theranostics trial in the area of sepsis.
Toraymyxin has been approved for therapeutic use in 18
countries, and has been used safely and effectively in more
than 80,000 patients to date. In March, 2009, Spectral
obtained the exclusive development and commercial rights in
the U.S. for Toraymyxin, and in November, 2010, signed an
exclusive distribution agreement for this product in Canada.
More than 250,000 patients are diagnosed with severe sepsis
and septic shock in North America each year, representing a
greater than $1 billion market opportunity for Spectral.
Spectral is listed on the Toronto Stock Exchange under the
symbol SDI.
For further information please visit www.spectraldx.com
For further information please contact:
Anthony Businskas
Executive Vice President and CFO
416-626-3233 ext. 2200
Adam Peeler Investor Relations TMX Equicom
416-815-0700 ext. 225 apeeler@equicomgroup.com
Information in this news release that is not current or historical factual information may constitute forward- looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
distribué par | Ce noodl a été diffusé par Spectral Diagnostics Inc. et initialement mise en ligne sur le site http://www.spectraldx.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-04 14:04:15 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
Spectral Diagnostics Provides Corporate Update |